ADC Therapeutics (ADCT) Liabilities and Shareholders Equity (2019 - 2026)

ADC Therapeutics (ADCT) has reported Liabilities and Shareholders Equity for 8 consecutive years, with $291.5 million the latest figure, recorded in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 6.96% year-over-year to $291.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (down 6.8% YoY) and the FY2025 annual result came in at $323.2 million, changed 0.36% from the prior year.
• Liabilities and Shareholders Equity declined to $291.5 million in Q1 2026 per ADCT's latest filing, from $323.2 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for ADCT reached as high as $581.9 million in Q1 2022 and fell as low as $272.5 million in Q1 2025.
• A 5-year average of $398.3 million and a median of $354.8 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity advanced 26.03% — and 2024, when it sank 34.15%.
• Year by year, Liabilities and Shareholders Equity stood at $490.9 million in 2022, then retreated by 27.72% to $354.8 million in 2023, then fell by 9.25% to $322.0 million in 2024, then climbed by 0.36% to $323.2 million in 2025, then slipped by 9.8% to $291.5 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $291.5 million, $323.2 million, and $289.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.